UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · IEX Real-Time Price · USD
14.26
+0.02 (0.14%)
Apr 18, 2024, 4:00 PM EDT - Market closed
UroGen Pharma Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for UroGen Pharma stock have an average target of 35.33, with a low estimate of 18 and a high estimate of 54. The average target predicts an increase of 147.76% from the current stock price of 14.26.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for UroGen Pharma stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $54 | Strong Buy | Reiterates | $54 | +278.68% | Apr 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $54 | Strong Buy | Reiterates | $54 | +278.68% | Apr 4, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $54 | Strong Buy | Reiterates | $54 | +278.68% | Mar 18, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $35 → $34 | Buy | Maintains | $35 → $34 | +138.43% | Mar 15, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $33 → $32 | Buy | Maintains | $33 → $32 | +124.40% | Nov 15, 2023 |
Financial Forecast
Revenue This Year
101.29M
from 82.71M
Increased by 22.46%
Revenue Next Year
189.77M
from 101.29M
Increased by 87.35%
EPS This Year
-3.72
from -3.55
EPS Next Year
-2.44
from -3.72
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 105.7M | 242.0M | 415.2M | 669.1M | 902.5M |
| Avg | 101.3M | 189.8M | 309.3M | 640.3M | 876.7M |
| Low | 95.9M | 160.2M | 231.5M | 605.9M | 842.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 27.7% | 138.9% | 118.8% | 116.3% | 41.0% |
| Avg | 22.5% | 87.4% | 63.0% | 107.0% | 36.9% |
| Low | 15.9% | 58.2% | 22.0% | 95.9% | 31.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.47 | -1.49 | 3.53 | 9.20 | 14.40 |
| Avg | -3.72 | -2.44 | 0.49 | 8.94 | 13.98 |
| Low | -3.82 | -3.07 | -1.37 | 8.58 | 13.44 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 1,765.7% | 61.1% |
| Avg | - | - | - | 1,712.4% | 56.5% |
| Low | - | - | - | 1,641.4% | 50.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.